Katsunobu Hagihara

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara et al. · Clinical Cancer Research · 2016 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

Miho Kazui, Yumi Nishiya, Tomoko Ishizuka et al. · Drug Metabolism and Disposition · 2009 · 821 citations

Medicine, Biochemistry, Pharmacology +17

Bystander killing effect of <scp>DS</scp>‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

Yusuke Ogitani, Katsunobu Hagihara, Masataka Oitate et al. · Cancer Science · 2016 · 715 citations · Full text

Medicine, Oncology, Pharmacology +17

The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite

Atsuhiro Sugidachi, Taketoshi Ogawa, Atsushi Kurihara et al. · Journal of Thrombosis and Haemostasis · 2007 · 218 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade

Chien-Chun Steven Pai, John Huang, Xiaoqing Lu et al. · Immunity · 2019 · 135 citations

Life Sciences, Immunology, Oncology +17